214 related articles for article (PubMed ID: 35235078)
1. A comprehensive review of official discount rates in guidelines of health economic evaluations over time: the trends and roots.
Khorasani E; Davari M; Kebriaeezadeh A; Fatemi F; Akbari Sari A; Varahrami V
Eur J Health Econ; 2022 Dec; 23(9):1577-1590. PubMed ID: 35235078
[TBL] [Abstract][Full Text] [Related]
2. Informative value of Patient Reported Outcomes (PRO) in Health Technology Assessment (HTA).
Brettschneider C; Lühmann D; Raspe H
GMS Health Technol Assess; 2011 Feb; 7():Doc01. PubMed ID: 21468289
[TBL] [Abstract][Full Text] [Related]
3. How is the Societal Perspective Defined in Health Technology Assessment? Guidelines from Around the Globe.
Avşar TS; Yang X; Lorgelly P
Pharmacoeconomics; 2023 Feb; 41(2):123-138. PubMed ID: 36471131
[TBL] [Abstract][Full Text] [Related]
4. National Healthcare Economic Evaluation Guidelines: A Cross-Country Comparison.
Sharma D; Aggarwal AK; Downey LE; Prinja S
Pharmacoecon Open; 2021 Sep; 5(3):349-364. PubMed ID: 33423205
[TBL] [Abstract][Full Text] [Related]
5. Qualitative comparative analysis of health economic evaluation guidelines for health technology assessment in European countries.
Zisis K; Naoum P; Athanasakis K
Int J Technol Assess Health Care; 2020 Dec; 37():e2. PubMed ID: 33298238
[TBL] [Abstract][Full Text] [Related]
6. Adherence to country-specific guidelines among economic evaluations undertaken in three high-income and middle-income countries: a systematic review.
Sharma D; Aggarwal AK; Wilkinson T; Isaranuwatchai W; Chauhan AS; Prinja S
Int J Technol Assess Health Care; 2021 Jul; 37(1):e73. PubMed ID: 34193325
[TBL] [Abstract][Full Text] [Related]
7. Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union.
Beletsi A; Koutrafouri V; Karampli E; Pavi E
Value Health Reg Issues; 2018 Sep; 16():81-91. PubMed ID: 30316029
[TBL] [Abstract][Full Text] [Related]
8. The practice of discounting in economic evaluations of healthcare interventions.
Smith DH; Gravelle H
Int J Technol Assess Health Care; 2001; 17(2):236-43. PubMed ID: 11446135
[TBL] [Abstract][Full Text] [Related]
9. Methods of international health technology assessment agencies for economic evaluations--a comparative analysis.
Mathes T; Jacobs E; Morfeld JC; Pieper D
BMC Health Serv Res; 2013 Sep; 13():371. PubMed ID: 24079858
[TBL] [Abstract][Full Text] [Related]
10. [The economic value of vaccinations: a systematic review of Italian economic evaluations and HTA reports].
Di Nardo F; Boccalini S; Calabrò GE; Marcellusi A; Ruggeri M; Bonanni P; Vitali R; Capannini E; Mennini FS; Cicchetti A; Panatto D; Gasparini R; Ricciardi W; De Waure C
Ig Sanita Pubbl; 2017; 73(5):453-471. PubMed ID: 29433132
[TBL] [Abstract][Full Text] [Related]
11. Over-, under- and misuse of pain treatment in Germany.
Dietl M; Korczak D
GMS Health Technol Assess; 2011 Apr; 7():Doc03. PubMed ID: 21522485
[TBL] [Abstract][Full Text] [Related]
12. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
13. Economic evaluations in fracture research an introduction with examples of foot fractures.
van den Boom N; van den Hurk AA; Kalmet P; Poeze M; Evers S
Injury; 2022 Mar; 53(3):895-903. PubMed ID: 35034777
[TBL] [Abstract][Full Text] [Related]
14. Methods for the comparative evaluation of pharmaceuticals.
Zentner A; Velasco-Garrido M; Busse R
GMS Health Technol Assess; 2005 Nov; 1():Doc09. PubMed ID: 21289930
[TBL] [Abstract][Full Text] [Related]
15. On discount rates for economic evaluations in global health.
Haacker M; Hallett TB; Atun R
Health Policy Plan; 2020 Feb; 35(1):107-114. PubMed ID: 31625564
[TBL] [Abstract][Full Text] [Related]
16. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I.
Hay JW; Smeeding J; Carroll NV; Drummond M; Garrison LP; Mansley EC; Mullins CD; Mycka JM; Seal B; Shi L
Value Health; 2010; 13(1):3-7. PubMed ID: 19874571
[TBL] [Abstract][Full Text] [Related]
17. Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines.
Kennedy-Martin M; Slaap B; Herdman M; van Reenen M; Kennedy-Martin T; Greiner W; Busschbach J; Boye KS
Eur J Health Econ; 2020 Nov; 21(8):1245-1257. PubMed ID: 32514643
[TBL] [Abstract][Full Text] [Related]
18. An International Review of Health Technology Assessment Approaches to Prescription Drugs and Their Ethical Principles.
Rand LZ; Kesselheim AS
J Law Med Ethics; 2020 Sep; 48(3):583-594. PubMed ID: 33021189
[TBL] [Abstract][Full Text] [Related]
19. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)--explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
Husereau D; Drummond M; Petrou S; Carswell C; Moher D; Greenberg D; Augustovski F; Briggs AH; Mauskopf J; Loder E;
Value Health; 2013; 16(2):231-50. PubMed ID: 23538175
[TBL] [Abstract][Full Text] [Related]
20. A methodological review of national and transnational pharmaceutical budget impact analysis guidelines for new drug submissions.
Foroutan N; Tarride JE; Xie F; Levine M
Clinicoecon Outcomes Res; 2018; 10():821-854. PubMed ID: 30538513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
